Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
Advagene Biopharma Co Ltd
ALK-Abello AS
Allergy Therapeutics Plc
Astellas Pharma Inc
Genetic Immunity Inc
Roxall Medizin GmbH
Stallergenes Greer Ltd
Worg Pharmaceuticals Hangzhou Co Ltd
House Dust Mite Allergy - Drug Profiles
AD-17002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-2390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
clustoid d. pteronyssinus - Drug Profile
Product Description
Mechanism Of Action
DermAll-HDM - Drug Profile
Product Description
Mechanism Of Action
standardized mite (Dermatophagoides farie + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
History of Events
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farie) allergen extract - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Grass Pollen Allergy and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
WP-1049 - Drug Profile
Product Description
Mechanism Of Action
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
May 31, 2021: Positive outcome of European decentralised registration procedure for Stallergenes Greer’s sublingual house dust mite allergen immunotherapy tablet
May 04, 2020: Stallergenes Greer submits a marketing authorisation application in Europe for its sublingual house dust mite allergen immunotherapy tablet
Jan 13, 2020: New clinical trial for ALK’s house dust mite tablet paves the way for early registration in Chi
Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears
May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial
Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint
May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
Feb 16, 2018: Torii Receives Approval for Additiol Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Cada
Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for House Dust Mite Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for House Dust Mite Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
House Dust Mite Allergy - Pipeline by Advagene Biopharma Co Ltd, 2022
House Dust Mite Allergy - Pipeline by ALK-Abello AS, 2022
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, 2022
House Dust Mite Allergy - Pipeline by Astellas Pharma Inc, 2022
House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, 2022
House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, 2022
House Dust Mite Allergy - Pipeline by Stallergenes Greer Ltd, 2022
House Dust Mite Allergy - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022
House Dust Mite Allergy - Dormant Projects, 2022
House Dust Mite Allergy - Discontinued Products, 2022